Indeed, we reported that downregulation of MCL-1 by RNAi or CRISPR can dramatically enhance the apoptotic response to navitoclax in prostate cancer cells in vitro and in vivo, with complete responses in established prostate cancer xenografts15. This evidence concerns the gene MCL1 and prostate cancer.